This ACC Top Ten covers the sensitive nature of successful negotiations of commercial leases in the United States.
Examine the connection between electronic discovery and due diligence, and get to know the evolving role of digital data management in mergers and acquisitions.
The development of blockchain technology is moving quickly, but there are still questions about government oversight and competition. Blockchain technology implicates privacy, antitrust, and securities law issues.
This InfoPAK (now known as ACC Guides) gives a succinct overview of merger control, regulatory framework and regulatory authorities in China.
AMD v. Intel is a valuable reminder of the importance of data preservation and ediscovery. Avoid unintentional evidence spoliation by implementing an effective preservation program — although initial costs may seem high, the risks of doing without could cripple a corporation’s capital and reputation.
Are you building or reviewing your organization's ESG program, with a focus on Europe? This tool presents sample frameworks for the environmental, social, and governance components: (i) key considerations, (ii) a detailed map of core ESG subtopics for each of the three ESG facets, and (ii) for each subtopic, potential goals, standards, and metrics, and more.
Examines the ethical rules and their interpretation by both courts and ethics' commissions to determine whether an agreement within a settlement package is unethical.
Anti-corruption is an important issue to address with your company. In this Leading Practice Profile, six companies explain how they implement and monitor their successful anti-corruption programs. It will also trace the evolution of anti-corruption laws.
This is a sample group and event sales agreement.
This guide explores key legal issues, rules, and developments regarding bribery and corruption across a range of jurisdictions.
This Wisdom of the Crowd (ACC member discussion), compiled from responses posted on the Nonprofit Organizations Forum, discusses whether it is common for non-profit entities to refuse to agree to representations & warranties in a contract.
Brands have become the currency of international trade. For in-house counsel, high-quality brands provide a bond of trust with your client’s consumers. Ensuring that your client’s brands are legally secure and high quality is challenging, especially in the case of brand migration.
This is a sample software license agreement.
You finally made it. No longer the lawyer, now the client. As head of regulatory affairs, you ask lawyers for advice (even though you know how to find the answers and often do). Life is less complicated, not having to worry about those pesky ethical rules. But are you really free of them? No one quite knows, although one can envision sanctions being imposed on a person who maintains her law degree in conduct that would clearly be violative of ethical norms. And the sanctions could adversely impact the client as well.
In this article, the ABA amends the ABA Model Rules of Professional Conduct dated August 2012, to provide guidance regarding the ethical implications of retaining lawyers and nonlawyers outside the firm to work on client matters (i.e. outsourcing)
Learn how public companies in Canada can structure their board, develop policies and procedures, handle disclosure obligations, and recent corporate governance developments.
On the transparency front, it was a busy summer for the European Federation of Pharmaceutical Industries and Associations (EFPIA). In the wake of recent ‘Sunshine’ legislation in France and other EU countries, and pending transparency trials before the Court of Justice of the European Union (CJEU), EFPIA adopted no less than two brand new transparency documents: a Disclosure – ‘Sunshine’ – Code and joint Principles for Responsible Clinical Trial Sharing. It also significantly strengthened the advertisement commitments in its existing Code on Interactions with HCPs.
Beginning on 1 January 2014, French pharmacists are now legally permitted to substitute a biosimilar for the prescribed (reference) biological medicine as long as the prescribing physician has not marked the prescription as “non-substitutable.” According to the new law, substitution is allowed only when initiating a course of treatment, and if the biosimilar belongs to the same group as the prescribed product, known as a “similar biologic group.” The criteria for inclusion in a “similar biologic group” have yet to be defined by the French healthcare authority (ANSM).
Learn about enforcement action taken by the US Centers for Medicare and Medicaid Services (CMS) in 2022 against hospitals, to enforce CMS's Hospital Price Transparency Rule that took effect on January 1, 2021.
Show results exclusively from the ACC Resource Library with customizable filters